Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Poll|Articles|November 5, 2025
Poll: Has the Shortage of IV Ativan Impacted Your Practice?
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Key Takeaways
- The shortage of IV Ativan poses challenges in managing psychiatric conditions, particularly catatonia, necessitating alternative treatment strategies.
- Increased incidences of catatonia may occur due to the difficulty in accessing IV Ativan, impacting patient care.
Answer our poll!
Advertisement
Psychiatric Times contributors have noted a challenge in their psychiatric practice: the shortage of intravenous (IV) Ativan.
Has the shortage of IV Ativan impacted your practice?
Have you noticed an increase in catatonia amongst your patients?
If you have noticed an increase in catatonia or a difficulty in accessing IV Ativan, reach out to us at
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
3
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
4
Hippocampal Generative Processes During Sleep Support Rapid Learning of New Associations
5